HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedEUCTR 2015-000749-21

Botulinumtoxin A for emotional stabilization in borderline personality disorder Botulinumtoxin A zur emotionalen Stabilisierung bei der Borderline-Persönlichkeitsstörung

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Personality disorders, Borderline personalityBiological
The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
Not clearly listed
Sponsor
Medizinische Hochschule Hannover
Sponsor type
Unknown or unclear
Study type
Biological
Intervention type
BIOLOGICAL
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Germany
Age range
Not clearly listed
Official registry ID
EUCTR 2015-000749-21
Official title
Botulinumtoxin A for emotional stabilization in borderline personality disorder Botulinumtoxin A zur emotionalen Stabilisierung bei der Borderline-Persönlichkeitsstörung

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: EUCTR 2015-000749-21. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Germany

Compensation and expense reimbursement have not been verified for this summary.

Checked Official study record (opens in a new tab)
Registry details
Registry conditions (original wording)

Borderline personality disorder Borderline-Persönlichkeitsstörung

Historical country statuses
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Medizinische Hochschule Hannover.

Is this study still recruiting?

The historical registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
CompletedEUCTR 2020-003469-20

A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.